PDA

View Full Version : Masteron® (drostanolone propionate)



akn
05-13-2014, 05:06 PM
Androgenic 25-40
Anabolic 62-130
Chemical Names 2alpha-methyl-androstan-3-one-17beta-ol
2aIpha-methyl-dihydrotestosterone
Estrogenic Activity none
Progestational Activity no data available (low)

Description:
Drostanolone propionate is an injectable anabolic steroid
derived from dihydrotestosterone (DHT). Here, the DHT
backbone has been modified with a 2-methyl group to
increase its anabolic properties, making this agent
significantly more effective at promoting the growth of
muscle tissue than its non-methylated parent.
Drostanolone propionate is described in product literature
as a "steroid with powerful anabolic and anti-estrogenic
properties," and indeed does seem to share some of both
properties. Admittedly, however, its anabolic properties are
more properly described as moderate, especially when
placed in the context of other agents. The drug is most
often used by dieting bodybuilders and athletes in speed
sports, where it is highly favored for its ability to produce
solid increases in lean muscle mass and strength, which are
usually accompanied by reductions in body fat level and
minimal side effects.
History:
Drostanolone propionate was first described in 1959.591
Syntex developed the agent alongside such other wellknown
steroids as Anadrol and methyldrostanolone
(Superdrol), also first described in the same paper.
Drostanolone propionate would be introduced as a
prescription drug product approximately a decade later.
Lilly had an agreement with Syntex to split certain research
and development costs in exchange for the rights to
market the results of that research. Lilly would, therefore,
sell drostanolone propionate in the u.s. under the Drolban
brand name, while Syntex would sell/license it in other
markets. Products included Masteron in Belgium (SarvaSyntex)
and Portugal (Cilag), Masteril in the U.K. and
Bulgaria, and Metormon in Spain. Drostanolone propionate
was also found in such popular preparations as Permastril
(Cassenne, France), Mastisol (Shionogi, Japan), and
Masterid (Grunenthal, Germany Democratic Republic).
The U.S. Food and Drug Administration approved drostanolone propionate for the treatment of advanced
inoperable breast cancer in postmenopausal women. This
remained the principle clinical indication for the agent in
all international markets as well. The prescribing literature
reminds doctors and female patients that there is
considerably less virilization with drostanolone propionate
as compared to equal doses of testosterone propionate,
suggesting this was a much more comfortable alternative
to testosterone injections for the given audience. Still, the
given dosage level (300 mg per week) was relatively high,
and the literature also reminds us that mild virilization
symptoms still commonly occur, such as deepening of the
voice, acne, facial hair growth, and enlargement of the
clitoris. It also reports that marked virilization sometimes
follows long-term therapy.
While highly popular among athletes during the 1970's
and '80's, drostanolone propionate ultimately enjoyed
limited success as a prescription agent. Manufacturers
began voluntarily discontinuing sale of the agent in
various markets before long, likely due to the advent of
more effective therapies for breast cancer, as well as the
slow decline in steroid prescriptions for this phase of
treatment. One of the first preparations to go was the U.S.
Drolban, which was removed from market during the late
1980's. Permastril and Metormon were soon dropped as
well. The last remaining Western preparation containing
drostanolone propionate was Masteron from Belgium,
which disappeared by the late 1990's. Drostanolone
propionate remains listed on the U.S. Pharmacopias,
suggesting there is presently no legal roadblock to its sale,
although its reemergence as a prescription drug product
seems highly unlikely.
How Supplied:
Drostanolone propionate is no longer available as a
prescription drug preparation. When produced, it was
supplied in the form of 1 mL and 2 mL ampules and 10 mL
viais containing 50 mg/ml or 100 mg/ml of steroid in oil.
Structural Characteristics:
Drostanolone (also known as dromostanolone) is a
modified form of dihydrotestosterone. It differs by the
introduction of a methyl group at carbon-2 (alpha), which
considerably increases the anabolic strength of the
steroid by heightening its resistance to metabolism by the
3-hydroxysteroid dehydrogenase enzyme in skeletal
muscle tissue. Drostanolone propionate is a modified
form of drostanolone, where a carboxylic acid ester
(propionic acid) has been attached to the 17-beta
hydroxyl group. Esterified steroids are less polar than free
steroids, and are absorbed more slowly from the area of
injection. Once in the bloodstream, the ester is removed to
yield free (active) drostanolone. Esterified steroids are
designed to prolong the window of therapeutic effect
following administration, allowing for a less frequent
injection schedule compared to injections of free
(unesterified) steroid. The half-life of drostanolone
propionate is approximately two days after injection.
Side Effects (Estrogenic):
Drostanolone is not aromatized by the body, and is not
measurably estrogenic. An anti-estrogen is not necessary
when using this steroid, as gynecomastia should not be a
concern even among sensitive individuals. Since estrogen
is the usual culprit with water retention, drostanolone
instead produces a lean, quality look to the physique with
no fear of excess subcutaneous fluid retention. This makes
it a favorable steroid to use during cutting cycles, when
water and fat retention are major concerns. As a nonaromatizable
DHT derivative, drostanolone may impart an
anti-estrogenic effect, the drug competing with other
(aromatizable) substrates for binding to the aromatase
enzyme.
Side Effects (Androgenic):
Although classified as an anabolic steroid,androgenic side
effects are still possible with this substance, especially
with higher than normal therapeutic doses. This may
include bouts of oily skin, acne, and body/facial hair
growth. Anabolic/androgenic steroids may also aggravate
male pattern hair loss.Women are warned of the potential
virilizing effects of anabolic/androgenic steroids. These
may include a deepening of the voice, menstrual
irregularities, changes in skin texture, facial hair growth,
and clitoral enlargement. Drostanolone is a steroid with
relatively low androgenic activity relative to its tissuebuilding
actions, making the threshold for strong
androgenic side effects comparably higher than with
more androgenic agents such as testosterone,
methandrostenolone, or fluoxymesterone. Note that
drostanolone is unaffected by the 5-alpha reductase
enzyme, so its relative androgenicity is not affected by the
concurrent use of finasteride or dutasteride.
Side Effects (Hepatotoxicity):
Drostanolone is not c17-alpha alkylated, and not known
to have hepatotoxic properties. Liver toxicity is unlikely.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects
on serum cholesterol. This includes a tendency to reduce
HDL (good) cholesterol values and increase LDL (bad)
cholesterol values, which may shift the HDL to LDL
balance in a direction that favors greater risk of
arteriosclerosis. The relative impact of an
anabolic/androgenic steroid on serum lipids is dependant
on the dose, route of administration (oral vs. injectable),
type of steroid (aromatizable or non-aromatizable), and
level of resistance to hepatic metabolism. Drostanolone
shouId have a stronger negative effect on the hepatic
management of cholesterol than testosterone or
nandrolone due to its non-aromatizable nature, but a
weaker impact than c-17 alpha alkylated steroids.
Anabolic/androgenic steroids may also adversely affect
blood pressure and triglycerides, reduce endothelial
relaxation, and support left ventricular hypertrophy, all
potentially increasing the risk of cardiovascular disease
and myocardial infarction.
To help reduce cardiovascular strain it is advised to
maintain an active cardiovascular exercise program and
minimize the intake of saturated fats, cholesterol, and
simple carbohydrates at all times during active AAS
administration. Supplementing with fish oils (4 grams per
day) and a natural cholesterol/antioxidant formula such as
Lipid Stabil or a product with comparable ingredients is
also recommended.
Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses
sufficient to promote muscle gain are expected to
suppress endogenous testosterone production. Without
the intervention of testosterone-stimulating substances,
testosterone levels should return to normal within 1-4
months of drug secession. Note that prolonged
hypogonadotrophic hypogonadism can develop
secondary to steroid abuse, necessitating medical
intervention.
The above side effects are not inclusive. For more detailed
discussion ofpotential side effects, see the Steroid Side Effects
section of this book.
Administration (Men):
Drostanolone propionate was not FDA approved for use
in men. Prescribing guidelines are unavailable. For physique- or performance-enhancing purposes, this drug
is usually injected three times per week. The total weekly
dosage is typically 200-400 mg, which is taken for 6-12
weeks. This level of use is sufficient to provide measurable
gains in lean muscle mass and strength.
Drostanolone propionate is often combined with other
steroids for an enhanced effect. Common stacks include
an injectable anabolic such as Deca-Durabolin®
(nandrolone decanoate) or Equipoise® (boldenone
undecylenate), which can provide notably enhanced
muscle gains without excessive water retention. For mass
gains, it is often combined with an injectable testosterone.
The result here can be solid muscle gain, with a lower level
of water retention and other estrogenic side effects than if
these steroids were used alone (usually in higher doses).
Masteron, however, is most commonly applied during
cutting phases of training. Here it is often combined with
other non-aromatizable steroids such as Winstrol®,
Primobolan®, Parabolan, or Anavar, which can greatly aid
muscle retention and fat loss, during a period which can
be very catabolic without steroids.
Administration (Women):
The prescribing guidelines for Drolban recommended a
dose of 100 mg given three times per week. Therapy is
given for a minimum of 8 to 12 weeks before an
evaluation of its efficacy is made. If successful, the drug
may be continued for as long as satisfactory results are
obtained. Note that virilization symptoms were common
at the recommended dosage. When used for physique- or
performance-enhancing purposes, a dosage of 50 mg per
week is most common, taken for 4 to 6 weeks. Virilization
symptoms are rare in doses of 100 mg per week or below.
Note that due to the short-acting nature of the
propionate ester, the total weekly dosage is usually
subdivided into smaller injections given once every
second or third day.
Availability:
The original Syntex Masteron is now unavailable on the
black market. It was discontinued in Europe years ago. No
old lots should still be circulating, meaning that there is no
legitimate source for brand name product Masteron
anywhere.
Other legitimate pharmaceutical brands are almost
nonexistent. There is a version of drostanolone sold in
Myanmar by the Xelox Company called Dromostan. It
contains base drostanolone only, not drostanolone
propionate. Although unconfirmed by lab testing, this is a
legit company, hopefully making a legit product. If so, it
would be only the second real drostanolone currently
sold worldwide. Due to the lack of an ester, injections
would best be given every 2 days with this product, just
short of the 3-4 typically used with Masteron.
In addition to the above, there are numerous
underground labs producing drostanolone propionate at
this time. Again, make sure you understand the inherent
risks of buying underground products before making
such a purchase.These risks can involve more than just the
loss of money, as underground products are not often
produced in a proper sterile (pharmaceutical level)
environment.